Galderma: 'Clear' (IGA 0) Rosacea Patients Experience a Delayed Time to Relapse

PR70114

LAUSANNE, Switzerland, Sept. 16, 2017, /PRNewswire=KYODO JBN/--

Today, the results of a pooled analysis of four Galderma-sponsored studies

evaluating the use of topical therapies for the treatment of inflammatory

papules and pustules of rosacea were presented at the 26th European Academy of

Dermatology and Venereology Congress in Geneva, Switzerland. The success of

rosacea treatment is usually defined as a score of 1 ('almost clear') or 0

('clear') on the 5-point Investigator Global Assessment (IGA) scale. The new

analysis reports that rosacea patients who achieve 'clear' (IGA 0), not only

experience a more complete reduction in inflammatory lesions compared with

patients who achieve 'almost clear' (IGA 1), but also an extended time to

relapse that is associated with improved quality of life.

The analysis, titled 'Defining treatment success in rosacea as 'clear' may

provide multiple patient benefits: Results of a pooled analysis,' is the

first-of-its-kind to report on the differences in patient-reported outcomes,

quality of life, and time to relapse associated with 'clear' (IGA 0) and

'almost clear' (IGA 1) patients.

"Rosacea is a chronic dermatological disease with remissions and exacerbations.

Improving treatment options with earlier effective treatment and longer

remission times may not only control symptoms, but also delay progression of

the disease," commented study author Guy Webster, Thomas Jefferson University,

Philadelphia, PA. "This first-of-its-kind analysis shows that both remission

time and quality of life are improved if patients achieve an endpoint of

'clear' (IGA 0), compared with patients who achieve 'almost clear' (IGA 1)."

In the analysis, patients who achieved 'clear' (IGA 0) were associated with a

delayed time to relapse of more than 5 months, compared with patients who

achieved 'almost clear' (IGA 1). At 8-month follow-up, twice as many patients

who had achieved 'clear' (IGA 0) remained free of treatment compared with

patients who had achieved 'almost clear' (IGA 1) (54% vs. 23%). The authors

stated that this delayed time to relapse may contribute to improved quality of

life and satisfaction with treatment, both in the short term and over the long

term. In addition, one-third more 'clear' (IGA 0) patients than 'almost clear'

(IGA 1) patients (59% vs. 44%) reported a clinically meaningful difference

(≥4 points) in Dermatology Life Quality Index score.

"Because the signs of rosacea are clearly visibly on the face, this

inflammatory skin disease is known to have a significant impact on quality of

life, with patients reporting embarrassment, anxiety, depression, and low

self-confidence," said Gregor Schäfer, Medical Lead at Galderma. "Galderma's

rosacea franchise provides healthcare professionals with increased options for

addressing important patient needs, including quality of life."

For related multimedia resources and additional information about the CLEAR

pooled analysis, please visit www.epresspack.net/galderma-clear/.

Reference:   

Abstract 1685 presented by Jerry Tan at the European Academy of Dermatology and

Venereology congress 2017, Geneva, Switzerland

About Rosacea

Rosacea is a common inflammatory skin disease that presents variable clinical

characteristics, of which the most common are flushing, permanent erythema, and

inflammatory lesions. It mainly affects the central areas of the face, such as

the cheeks and nose. The disease can affect both adult men and women, usually

after the age of 30. Additionally, symptoms such as stinging, burning and

increased sensitivity of the skin are common. The eyes are often affected, and

might present as red, dry or itchy.

Although the cause of the disease is still under debate, various trigger

factors are known, including spicy foods, alcohol, emotional stress,

sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites,

can also be found in the skin in an elevated quantity in people with rosacea.

Rosacea may worsen over time if left untreated. People that suspect they suffer

from rosacea should visit their dermatologist or healthcare provider for

diagnosis and discuss what treatment is right for them. Because rosacea is a

highly visible disease, it is known to cause embarrassment and anxiety in some

patients, which in turn may cause frustration and have a negative impact on

their social life.

About Galderma

Galderma, Nestlé Skin Health's medical solutions business, was created in 1981

and is now present in over 100 countries with an extensive product portfolio to

treat a range of dermatological conditions. The company partners with health

care practitioners around the world to meet the skin health needs of people

throughout their lifetime. Galderma is a leader in research and development of

scientifically defined and medically proven solutions for the skin, hair and

nails. For more information, please visit www.galderma.com.

SOURCE: Galderma